IJRR

International Journal of Research and Review

| Home | Current Issue | Archive | Instructions to Authors | Journals |

Year: 2026 | Month: April | Volume: 13 | Issue: 4 | Pages: 90-96

DOI: https://doi.org/10.52403/ijrr.20260409

Chemically Modified Curcumin as a Host Modulation Therapy in Periodontitis: An Overview

Supriya Yadav1, Shailendra S Chauhan2, Satendra Sharma3, Nidhi Bharti4, Gauranshi Gupta5

1Department of Periodontology and Oral Implantology, 2Head of the Department, Department of Periodontology and Oral Implantology, 3Professor, Department of Periodontology and Oral Implantology, 4,5Department of Periodontology and Oral Implantology,
K.D. Dental College & Hospital, Mathura, India.

Corresponding Author: Dr. Supriya Yadav

ABSTRACT

Chemically modified curcumin (CMC) represents a novel host-modulating approach for managing periodontitis, designed to overcome the poor bioavailability and instability of natural curcumin. Among its analogues, CMC2.24, a triketonic zinc-binding derivative, exhibits potent anti-inflammatory, antioxidant, and anti-collagenolytic effects. Preclinical studies demonstrate that CMC2.24 effectively suppresses NF-κB and MMP activity, reduces pro-inflammatory cytokines, and preserves alveolar bone in ligature- and diabetes-induced periodontitis models, with minimal cytotoxicity. Various formulations, including nanoparticles, gels, and collagen scaffolds, enhance local delivery and therapeutic retention. Although no human trials are yet available, the robust preclinical evidence positions CMC derivatives as promising, safe, and biocompatible adjuncts to conventional periodontal therapy. Future research should focus on standardized formulations, long-term safety, and well-controlled clinical trials to confirm translational efficacy.

Keywords: Chemically modified curcumin, CMC2.24, Curcumin Analogues, Periodontitis, Host Modulation, MMP Inhibition, NF-κB, Local Delivery

[PDF Full Text]